Product and intended use
State material behavior, dosage form, product sensitivity, sample status and intended use.
Translate product contact, cleanability, cross-contamination, documentation, GMP or cGMP inputs, U.S. market requirements and validation support into a written equipment scope.
A pharma-sensitive review starts with product and dosage form, target market, factory quality system, pack, film, sample status, site interfaces, output target and named buyer approval responsibilities.
State material behavior, dosage form, product sensitivity, sample status and intended use.
State where the packed product will be manufactured and marketed and who identifies applicable requirements.
Provide dose, Stick Pack or sachet geometry, film, output target, inspection and downstream boundary.
Name who approves the URS, risks, contact and cleaning inputs, tests, documents and acceptance.
Review surfaces, hopper, hoses, seals, pump or metering parts, nozzles, access, drainability, retained material, cleaning method, cross-contamination, changeover, calibration and records with the buyer's quality team.

Map every project-specific product-contact component and hold-up point.
Define method, access, disassembly, agents, verification responsibility and restart basis.
Define product sequence, retained material, segregation, inspection and buyer acceptance.
Define applicable instruments, record expectations, responsibilities and approved evidence.
Metering, Stick Pack or sachet geometry, film, registration, product carryover, seal inspection and reject or downstream handoff require one written project basis.
Select a candidate metering path only after product behavior, target dose, contact and cleaning inputs are known.
Review engineering pageDefine Stick Pack or sachet dimensions, film, opening, print and seal requirements.
Review engineering pageDefine seal-zone risks, inspection method, reject responsibility and accepted-pack evidence.
Use a real sample where behavior can change contact, filling, cut-off, cleaning or sealing.
Review engineering page
The visible Service properties below are the authoritative structured-data properties. They describe required inputs and conditional support, not a standard pharmaceutical machine specification.
| Project decision | Visible service boundary |
|---|---|
| Project and market inputs | Define the product and dosage form, intended use, target market, buyer quality system, pack, film, output target, site conditions and named approval responsibilities. |
| Product-contact and cleanability inputs | Define contact surfaces and components, access, drainability, cleaning method, residue, cross-contamination, changeover, calibration and record expectations as project requirements. |
| Validation-readiness support | Support may include where specified in the approved contract: URS response, risk review, DQ, FAT/SAT protocols, IQ/OQ support, calibration records and material-compliance documents. |
| Manufacturing-system evidence | Guangdong Kinghanlong Intelligent Equipment Technology Co., Ltd.; ISO 9001 98926Q0112R153, scope production of packing machines, certificate dates 2026-04-23—2029-04-22; SGS/Made-in-China report QIP-ASR2511099, audit date 2025-09-20. |
The buyer identifies applicable product, quality, regulatory, site and acceptance requirements. AIX records agreed equipment-supplier responses, deliverables, interfaces, support and exclusions in approved project documents.
GMP or cGMP and U.S. market inputs vary by product, dosage form, intended use, site and market. FDA is not presented as an approving or certifying body for this packaging machine.
Translate the buyer's applicable categories into URS inputs, risk questions, supplier responses, tests, documents and acceptance responsibilities.
No machine approval or certification by FDA, no GMP or cGMP machine certification, and no unconditional GMP or cGMP compliance claim is made.
ISO 9001 certificate 98926Q0112R153
Scope: production of packing machines
Certificate dates: 2026-04-23—2029-04-22
Audit date: 2025-09-20. It supports manufacturing-process, quality-control, R&D and real-factory context at that audit date.
Project support may include where specified in the approved contract. Nothing on this page states that a machine, process or customer project is already validated or that document deliverables form a standard set.
Define supplier responses, assumptions, open risks, interfaces, responsibilities and exclusions.
Define the protocol purpose, reviewed scope, conditions, observations, records and approval responsibilities.
Define supplier support, site responsibility, prerequisites, evidence and exclusions for the approved project.
Define calibration records and material-compliance documents that may be included under the approved contract.
The public route helps a similar buyer identify product-contact, cleaning, gel filling, documentation and market-requirement questions. It is not regulatory, qualification, validation, installation or performance proof.
Public material-and-pack route context only. It does not establish the installed machine, model, lane count, speed, accuracy, configuration, compliance status, validation outcome or customer result. It does not establish FDA approval, GMP compliance, qualification or validation.
Review bounded public referenceNo. FDA does not approve this packaging machine, and GMP or cGMP requirements must be mapped by intended use, product, site, market and the buyer's quality responsibilities.
Document deliverables are not a fixed public set. Support may include where specified in the approved contract and must be defined with responsibilities, deliverables, exclusions and acceptance in writing.
Bring product and sample status, dosage form, pack and film, product-contact and cleaning requirements, target market, URS or quality inputs, site interfaces and required acceptance records.